Optimising therapy for insulin-treated type 2 diabetes mellitus

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) management requires addressing hyperglycemia and associated risk factors.
• Insulin therapy is indicated when diet and oral antihyperglycemic agents fail to achieve adequate glycemic control.
• Oral antihyperglycemic agents can be used in combination with insulin to enhance efficacy and mitigate side effects.

Purpose of the Study:

• To provide a guide for the optimal use of insulin in type 2 diabetes mellitus.
• To outline individualized strategies for achieving metabolic control while preserving well-being.
• To discuss the benefits of combining insulin with oral antihyperglycemic agents.

Main Methods:

• Review of pathophysiological considerations and drug actions in T2DM.
• Analysis of evidence supporting combination therapy versus insulin monotherapy.
• Evaluation of different insulin regimens and oral agent combinations.

Main Results:

• Combination therapy (insulin with oral agents) can improve glycemic control, reduce insulin dosage, and counteract weight gain.
• Combining insulin with metformin or thiazolidinediones directly targets insulin resistance.
• Bedtime insulin with metformin showed significant benefits in a 1-year randomized study.

Conclusions:

• Optimizing oral antihyperglycemic therapy before initiating insulin is recommended.
• Combination therapy offers advantages over insulin monotherapy, including potentially reduced hypoglycemia.
• Individualized insulin regimens, starting with basal or premixed insulin, should be tailored to patient needs.